Grosset, D.G., Antonini, A., Canesi, M., Pezzoli, G., Lees, A., Shaw, K., Esther Cubo, E., Martinez-Martin, P., Rascol, O., Negre-Pages, L., Senard, A., Schwarz, J., Strecker, K., Reichmann, H., Storch, A., L?hle, M., Stocchi, F. and Grosset, K. (2009) Adherence to Antiparkinson Medication in a Multicenter European Study. Movement Disorders, 24, 826-832. http://dx.doi.org/10.1002/mds.22112

has been cited by the following article:

• TITLE: Self-Reported Adherence after Overnight Switching from Immediate- to Extended-Release Pramipexole in Parkinson’s Disease

  AUTHORS: Mutsumi Iijima, Mikio Osawa, Kenji Maruyama, Shinichiro Uchiyama, Kazuo Kitagawa

  KEYWORDS: Parkinson’s Disease, Timing Adherence, Pramipexole, Extended-Release, Immediate-Release, Motor Function

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.4 No.1, February 5, 2015

  ABSTRACT: Background: Drug adherence decreased in patients with Parkinson’ s disease (PD) because of taking many different types of drugs. We evaluated drug adherence after switching from immediate-release (IR) to once-daily extended-release (ER) pramipexole (PPX) in PD. Methods: This study included 35 PD patients (20 men, 15 women); 10 were taking oral PPX alone, and 25 were also using another anti-PD drug. PPX-IR was switched overnight to PPX-ER without gradual tapering. One month after switching, improvement in timing adherence and reduction in medication burden were evaluated by a questionnaire using a visual analog scale (VAS) (0: No change; 10: Better). Motor function was assessed using part III of the Unified Parkinson’s Disease Rating Scale (UPDRS). Results: The VAS score for improvement in timing adherence was 8.1 ± 0.5 (mean ± standard error), and that for reduction in medication burden was 7.3 ± 0.6. There was a significant negative correlation (ρ = -0.43, p = 0.01) between the VAS score and number of types of medications. The UPDRS part III score improved significantly after switching (p